



# SUVEN Life Sciences

## **Communication to investors** **June 2017**

14-Aug-17

*2017-18 Q1 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

# FINANCIAL QUICK VIEW

## Quarter 1 – June 2017



	Q1-FY18 to Q4-FY17	Q1-FY18 to Q1-FY17
Growth in Revenue	-20.77%	6.48%
Growth in PAT	-26.70%	-8.98%
Growth in EBIDTA	-4.61%	6.41%
Growth Pre-R&D EBIDTA	-7.83%	7.02%
Increase in R&D costs	-16.77%	9.00%


# MAJOR PROFITABILITY RATIOS



	30 Jun 2017	31 Mar 2017	30 Jun 2016
PAT to Income	20.15%	21.78%	23.57%
EBIDTA to Income	34.70%	28.82%	34.72%
Cash Flow to Income	23.69%	25.66%	27.06%
Pre-R&D EBITDA to Income	45.62%	39.22%	45.39%
R&D to Income	10.92%	10.39%	10.67%



# INCOME COMPARISON




14-Aug-17

2017-18 Q1 results



# PROFIT COMPARISON




14-Aug-17

2017-18 Q1 results



# EBIDTA COMPARISON




14-Aug-17

2017-18 Q1 results



# R & D – EXPENDITURE




14-Aug-17

2017-18 Q1 results





# PRE-R&D EBIDTA




14-Aug-17

2017-18 Q1 results



# PRE-R&D CASHFLOW



14-Aug-17

2017-18 Q1 results



# Financial Snapshot

	All figures are in INR Million, other than ratios and EPS				
	Q1 FY17-18	Q4 FY16-17	Growth %	Q1 FY16-17	Growth %
Income	1,466.42	1,850.86	-20.77%	1,377.24	6.48%
Pre-R&D EBITDA	668.97	725.84	-7.83%	625.08	7.02%
Pre-R&D EBITDA Margin	45.62%	39.22%		45.39%	
EBITDA	508.86	533.46	-4.61%	478.18	6.41%
EBITDA Margin	34.70%	28.82%		34.72%	
EBIT	456.94	461.63	-1.02%	430.12	6.23%
EBIT Margin	31.16%	24.94%		31.23%	
Financing costs	12.70	15.68		15.96	
Financing costs to Income	0.87%	0.85%		1.16%	
Profit before tax (PBT)	444.23	445.95	-0.39%	414.17	7.26%
Taxes	148.77	42.84	247.30%	89.54	66.16%
Taxes to PBT	33.49%	9.61%		21.62%	
Net Profit after tax	295.46	403.11	-26.70%	324.63	-8.98%
NP Margin	20.15%	21.78%		23.57%	
EPS (Re)	2.32	3.17		2.55	
Paid up share capital (Re. 1/shr)	127.28	127.28		127.28	
Depreciation	51.92	71.83		48.06	
R&D expenses	160.12	192.38	-16.77%	146.90	9.00%
R&D to Income	10.92%	10.39%		10.67%	

14-Aug-17

2017-18 Q1 results



# News Release

- SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer's initiated in 76 investigator sites in USA and so far enrolled 269 patients in the study.
- During the period Suven initiated Phase 1 trials for SUVN-911, the molecule indicated for Major Depressive Disorder (MDD)
- During the period Suven secures 6 product patents covering Australia, USA, Israel, Macau and South Korea
- Suven participated in B&K - Annual Investors Conference – Trinity India 2017, held in Mumbai in June 2017
- Suven participated in Centrum Corporate Connect 2017, held in Mumbai in June 2017
- Suven presented in Alzheimer's conference, AAIC>2017 held in London in July 2017.